AZN - AstraZeneca PLC

NYSE - NYSE Delayed Price. Currency in USD
49.31
+0.20 (+0.41%)
At close: 4:00PM EST

49.31 0.00 (0.00%)
After hours: 4:15PM EST

Stock chart is not supported by your current browser
Previous close49.11
Open49.36
Bid48.76 x 1200
Ask49.34 x 1400
Day's range49.06 - 49.56
52-week range36.83 - 51.55
Volume3,260,479
Avg. volume2,743,816
Market cap128.79B
Beta (5Y monthly)0.27
PE ratio (TTM)96.12
EPS (TTM)0.51
Earnings dateN/A
Forward dividend & yield1.40 (2.93%)
Ex-dividend date07-Aug-2019
1y target est53.05
  • GlobeNewswire

    NeoTX Closes $45 Million Series C Financing

    REHOVOT, Israel, Feb. 19, 2020 -- NeoTX Therapeutics, a clinical-stage biotechnology company leveraging its proprietary Selective T cell Redirection (STR) platform to develop.

  • AstraZeneca's (AZN) Q4 Earnings and Sales Miss Estimates
    Zacks

    AstraZeneca's (AZN) Q4 Earnings and Sales Miss Estimates

    AstraZeneca (AZN) misses estimates for earnings and sales. However, new drugs, mainly cancer medicines, continue to drive product sales higher.

  • AstraZeneca's CEO reaffirms 2021 targets
    Reuters

    AstraZeneca's CEO reaffirms 2021 targets

    AstraZeneca is fully on track to reach its earnings goal for next year, its chief executive told Reuters on Friday after the British drugmaker's quarterly earnings missed market expectations. AstraZeneca is moving into a third year of sales growth after changes driven by Soriot and now has nine drugs with annual sales of more than $1 billion but analysts and investors have been looking for clues whether the company's earnings growth would keep up. The company's 2019 operating margin, or earnings before interest and tax over total revenue, was 26%.

  • AstraZeneca braces for coronavirus hit, but no impact so far
    Reuters

    AstraZeneca braces for coronavirus hit, but no impact so far

    The company, moving into a third year of growth, predicted revenues would rise by a high single-digit to a low double-digit percentage at constant exchange rates this year, compared with 13% in 2019. Analysts are currently forecasting growth of 10%, according to Refinitiv data, although Jefferies analysts said anything below a double-digit estimate could be a disappointment.

  • FTSE 100 ends week lower after week AstraZeneca, RBS results
    Reuters

    FTSE 100 ends week lower after week AstraZeneca, RBS results

    The FTSE 100 index ended the Valentine's Day trading session 0.6% lower, down 0.8% for the week, while the midcap bourse rose 0.5% as it drew strength from the pound. Global markets are expecting stimulus from central banks as new coronavirus showed no signs of peaking. U.S. Federal Reserve Chair Jerome Powell had last week warned that the economic impact from the outbreak could spill over globally.

  • Financial Times

    AstraZeneca warns of coronavirus hit to growth

    AstraZeneca has warned of the “unfavourable impact” on its business of the coronavirus outbreak, making clear that the unfolding epidemic has injected uncertainty into its growth forecasts. The Anglo-Swedish drugmaker on Friday said that, depending on the impact of the virus, total revenue for this year was expected to increase “by a high single-digit to a low double-digit percentage”. Core earnings per share were expected to rise by a mid- to high-teens percentage.

  • Reuters

    RPT-FOCUS-Coronavirus outbreak begins to disrupt booming China drug trials

    The fast-spreading coronavirus is starting to disrupt testing of experimental medicines in China, posing a threat to plans by global drugmakers that have invested billions of dollars to harness the potential of the Asian economic powerhouse. The U.S. clinical trials database lists nearly 500 studies with a site in the city of Wuhan, which has endured the brunt of an outbreak that has killed more than 1,100 people and infected more than 44,000 in China. About 20% of global trials are now conducted in China, up from about 10% just five years ago, according to GlobalData Plc.

  • FibroGen's (FGEN) NDA for Roxadustat Accepted by the FDA
    Zacks

    FibroGen's (FGEN) NDA for Roxadustat Accepted by the FDA

    The FDA accepts FibroGen's (FGEN) NDA for roxadustat for the treatment of anemia of chronic kidney disease in both non-dialysis-dependent and dialysis-dependent patients.

  • GlobeNewswire

    FibroGen Announces U.S. FDA Acceptance of New Drug Application for Roxadustat for the Treatment of Anemia of Chronic Kidney Disease

    FibroGen, Inc. (FGEN) today announced that the U.S. Food and Drug Administration (FDA) has completed its filing review of its New Drug Application (NDA) for roxadustat for the treatment of anemia of chronic kidney disease (CKD), in both non-dialysis-dependent (NDD) and dialysis-dependent (DD) patients. The FDA has set a Prescription Drug User Fee Act (PDUFA) date of December 20, 2020. “The FDA’s acceptance of the roxadustat new drug application is a critical step towards providing a new treatment option in the United States for chronic kidney disease patients suffering from anemia, a serious and often life-threatening disease,” said Enrique Conterno, Chief Executive Officer, FibroGen.

  • What's in Store for AstraZeneca (AZN) This Earnings Season?
    Zacks

    What's in Store for AstraZeneca (AZN) This Earnings Season?

    AstraZeneca's (AZN) fourth-quarter results are expected to reflect the impact of new drug sales.

  • Allergan (AGN) to Report Q4 Earnings: What's in the Cards?
    Zacks

    Allergan (AGN) to Report Q4 Earnings: What's in the Cards?

    Allergan's (AGN) key products like Botox are likely to have provided top-line support in Q4 as loss of exclusivity of several products hurts sales.

  • Merck (MRK) Beats on Q4 Earnings, Plans Women Health Spin Off
    Zacks

    Merck (MRK) Beats on Q4 Earnings, Plans Women Health Spin Off

    Merck (MRK) beats estimates for earnings but misses the same for sales in fourth-quarter 2019. The company plans to spin off Women Health drugs/biosimilars into new company. Shares down.

  • Merck (MRK) to Report Q4 Earnings: Is a Beat in the Offing?
    Zacks

    Merck (MRK) to Report Q4 Earnings: Is a Beat in the Offing?

    Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to have driven Q4 sales. However, genericization of key drugs and increased competition might have been concerns.

  • Pharma Stock Roundup: LLY, PFE Q4 Results, JNJ's Coronavirus Vaccine Initiative
    Zacks

    Pharma Stock Roundup: LLY, PFE Q4 Results, JNJ's Coronavirus Vaccine Initiative

    Lilly (LLY), Pfizer (PFE) and Novartis (NVS) announce Q4 results.

  • Business Wire

    Educational Lung Cancer Event Coming to The Villages to Raise Awareness of the State’s High Rate of Lung Cancer

    In an effort to show how advances in science are being harnessed in the fight against lung cancer, The LungXperience, an educational exhibit sponsored by AstraZeneca, will be making a stop at The Villages Balloon Festival. The free exhibit, designed to help educate the public about lung cancer, will be at The Villages Polo Club on February 7 from 2 PM to 9 PM and February 8 from 2 PM to 9 PM.

  • Allergan to Divest Brazikumab, Zenpep to Close AbbVie Merger
    Zacks

    Allergan to Divest Brazikumab, Zenpep to Close AbbVie Merger

    Allergan (AGN) to divest autoimmune candidate, brazikumab and drug Zenpep in connection with its pending merger with AbbVie.

  • Business Wire

    BRILINTA Met Primary Endpoint in the Phase III THALES Trial in Stroke

    High-level results from the Phase III THALES trial showed AstraZeneca’s BRILINTA (ticagrelor) 90 mg used twice daily and taken with aspirin for 30 days, reached a statistically significant and clinically meaningful reduction in the risk of the primary composite endpoint of stroke and death, compared to aspirin alone.

  • AbbVie-Allergan $63 billion deal aided by Nestle, AstraZeneca buys
    Reuters

    AbbVie-Allergan $63 billion deal aided by Nestle, AstraZeneca buys

    U.S. drugmaker AbbVie's $63 billion tie-up with Allergan is getting help from Nestle and AstraZeneca buying up products the Irish-domiciled company is shedding to placate regulators. AbbVie is swallowing Allergan to give it control of the lucrative wrinkle treatment Botox and to diversify a portfolio heavily dependent on its $19-billion-per-year arthritis drug Humira, the world's best-selling medicine that is advancing toward U.S. patent expiration. Swiss food group Nestle bulked up its medical nutrition business with Allergan's Zenpep, a product with 2018 sales of $237 million which treats people whose pancreases do not provide enough enzymes to digest fats, proteins and sugars.

  • Roche's Urothelial Cancer Study on Tecentriq Disappoints
    Zacks

    Roche's Urothelial Cancer Study on Tecentriq Disappoints

    Roche's (RHHBY) study on Tecentriq in muscle-invasive urothelial cancer fails to meet goals.

  • Pharma Stock Roundup: J&J's Mixed Q4, Roche & Novartis' New Drugs Approval in EU
    Zacks

    Pharma Stock Roundup: J&J's Mixed Q4, Roche & Novartis' New Drugs Approval in EU

    J&J (JNJ) announces mixed Q4 results. Roche's (RHHBY) lymphoma drug, Polivy and Novartis' (NVS) Mayzent for secondary progressive multiple sclerosis (SPMS) get approval in Europe.

  • Pfizer (PFE) Q4 Earnings Coming Up: What's in the Cards?
    Zacks

    Pfizer (PFE) Q4 Earnings Coming Up: What's in the Cards?

    While Pfizer's (PFE) key drugs like Ibrance, biosimilars and strong emerging market sales are likely to have driven Q4 sales, generic competition for Lyrica is likely to have hurt the same.

  • Health stocks reverse coronavirus gains as one analyst says the market is overreacting
    Yahoo Finance

    Health stocks reverse coronavirus gains as one analyst says the market is overreacting

    Virus originating in Wuhan, China affected stock markets Tuesday, but one analyst said reactions were too strong.

  • 5 Big Drug/Biotech Stocks Set to Trump Q4 Earnings Estimates
    Zacks

    5 Big Drug/Biotech Stocks Set to Trump Q4 Earnings Estimates

    Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.

  • Top Stock Research Reports for Roche, Royal Dutch Shell & Citigroup
    Zacks

    Top Stock Research Reports for Roche, Royal Dutch Shell & Citigroup

    Top Stock Research Reports for Roche, Royal Dutch Shell & Citigroup